Liraglutide: A once-daily human glucagon-like peptide-1 analogue

被引：7

作者：

Aimaretti, G. ^{[1
]}

机构：

[1] Univ A Avogadro Piemonte Orientale, Dept Clin & Expt Med, I-28100 Novara, Italy

来源：

JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION | 2009年 / 32卷 / 08期

关键词：

GLP-1; analogue; liraglutide; Type 2 diabetes mellitus; HUMAN GLP-1 ANALOG; BETA-CELL MASS; DERIVATIVE LIRAGLUTIDE; GLYCEMIC CONTROL; NN2211; HEALTHY; WEIGHT; GLUCOSE; SAFETY; PHARMACOKINETICS;

D O I：

10.1007/BF03345744

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：701 / 703

页数：3

共 22 条

[1] The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men [J].

Agerso, H ;

Jensen, LB ;

Elbrond, B ;

Rolan, P ;

Zdravkovic, M .

DIABETOLOGIA, 2002, 45 (02) :195-202

[2] The endocrine pancreas in non-diabetic rats after short-term and long-term treatment with the long-acting GLP-1 derivative NN2211 [J].

Bock, T ;

Pakkenberg, B ;

Buschard, K .

APMIS, 2003, 111 (12) :1117-1124

[3] The long-acting glucagon-like peptide-1 analogue, liraglutide, inhibits β-cell apoptosis in vitro [J].

Bregenbolt, S ;

Moldrup, A ;

Blume, N ;

Karlsen, AE ;

Friedrichsen, BN ;

Tornhave, D ;

Knudsen, LB ;

Petersen, JS .

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2005, 330 (02) :577-584

[4] The GLP-1 derivative NN2211 restores β-cell sensitivity to glucose in type 2 diabetic patients after a single dose [J].

Chang, AM ;

Jakobsen, G ;

Sturis, J ;

Smith, MJ ;

Bloem, CJ ;

An, B ;

Galecki, A ;

Halter, JB .

DIABETES, 2003, 52 (07) :1786-1791

[5] One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and α- and β-cell function and reduces endogenous glucose release in patients with type 2 diabetes [J].

Degn, KB ;

Juhl, CB ;

Sturis, J ;

Jakobsen, G ;

Brock, B ;

Chandramouli, V ;

Rungby, J ;

Landau, BR ;

Schmitz, O .

DIABETES, 2004, 53 (05) :1187-1194

[6] Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male subjects [J].

Elbrond, B ;

Jakobsen, S ;

Larsen, S ;

Agerso, H ;

Jensen, LB ;

Rolan, P ;

Sturis, J ;

Hatorp, V ;

Zdravkovic, M .

DIABETES CARE, 2002, 25 (08) :1398-1404

[7] Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans [J].

Flint, A ;

Raben, A ;

Astrup, A ;

Holst, JJ .

JOURNAL OF CLINICAL INVESTIGATION, 1998, 101 (03) :515-520

[8] Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial [J].

Garber, Alan ;

Henry, Robert ;

Ratner, Robert ;

Garcia-Hernandez, Pedro A. ;

Rodriguez-Pattzi, Hiromi ;

Olvera-Alvarez, Israel ;

Hale, Paula M. ;

Zdravkovic, Milan ;

Bode, Bruce .

LANCET, 2009, 373 (9662) :473-481

[9] Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes [J].

Juhl, CB ;

Hollingdal, M ;

Sturis, J ;

Jakobsen, G ;

Agerso, H ;

Veldhuis, J ;

Porksen, N ;

Schmitz, O .

DIABETES, 2002, 51 (02) :424-429

[10]

Madsbad Sten, 2009, Expert Rev Endocrinol Metab, V4, P119, DOI 10.1586/17446651.4.2.119

← 1 2 3 →